A team has created a biosynthetic pathway for E. coli that allows the bacteria to produce a common arthritis drug.
List view / Grid view
Filter the results
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Scientists have identified a potential alternative to antibiotics, a nutrient named taurine that helps the microbiome kill invading bacteria.
The role that retrons in bacteria has been discovered by researchers, who found they protect colonies when infected by viruses.
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Researchers have screened over 2,000 compounds to discover that rocaglates effectively combat C. auris, offering a potential new treatment.
A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
Researchers have found that using antibiotics in combination with cannabidiol (CBD) enhanced their effect against Staphylococcus aureus bacteria.
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
Researchers have developed a new combination of compounds called AB569 which has demonstrated success at fighting deadly pathgoens like Pseudomonas aeruginosa.